MindBio Therapeutics (FRA:WF60) Revenue: €0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:WF60 MindBio Therapeutics Corp FRA:WF60
37 GF Score
Price €0.13
! 1 Warning Sign
View Full Analysis

What is MindBio Therapeutics Revenue?

MindBio Therapeutics FRA:WF60 37 Revenue is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:WF60 with a GF Score™ of 37/100. The stock has 1 warning sign investors should review.

MindBio Therapeutics's revenue for the three months ended in Mar. 2026 was €0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil. MindBio Therapeutics's Revenue per Share for the three months ended in Mar. 2026 was €0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.


MindBio Therapeutics  (FRA:WF60) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


MindBio Therapeutics Revenue Related Terms


MindBio Therapeutics Revenue Historical Data

* Premium members only.

The historical data trend for MindBio Therapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindBio Therapeutics Revenue Chart

MindBio Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Revenue
0.00 0.00 0.00 0.00 0.00

MindBio Therapeutics Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:WF60 vs VRTX, REGN, RVMD: Revenue Comparison

For the Biotechnology subindustry, MindBio Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MindBio Therapeutics Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindBio Therapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where MindBio Therapeutics's Revenue falls into.


FRA:WF60
37GF Score
MindBio Therapeutics Corp FRA:WF60
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindBio Therapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of €0.00 Mil mean?
MindBio Therapeutics (FRA:WF60) has a Revenue of €0.00 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on MindBio Therapeutics and its competitors.
Is MindBio Therapeutics' Revenue too high?
MindBio Therapeutics' current Revenue is €0.00 Mil. Overall, MindBio Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does MindBio Therapeutics' Revenue compare to VRTX and REGN?
MindBio Therapeutics' Revenue of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on MindBio Therapeutics and its competitors. MindBio Therapeutics's current Revenue is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindBio Therapeutics stock overvalued right now?
MindBio Therapeutics (FRA:WF60) has a current Revenue of €0.00 Mil. The current Revenue is €0.00 Mil. MindBio Therapeutics' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For MindBio Therapeutics (FRA:WF60), the current Revenue is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MindBio Therapeutics Business Description

Other Exchanges MBIO:Canada
Address 91-97 William Steet, Level 4, Melbourne, VIC, AUS, 3000
MindBio Therapeutics Corp is engaged in the research, development, and testing of psychedelic substances as a potential treatment for the management of a broad range of mental health conditions. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the company's activities take place in Australia.
37GF Score

Get the complete analysis for FRA:WF60

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.13
Price